Baldoquin (hamstring) played in a minor-league game Thursday for the first time since April 12. Baldoquin missed over three weeks of action due to his hamstring injury, but he is back in action at High-A Inland Empire. He will turn 22 in mid-May, so he will have an opportunity to move up a level at some point this season if he can improve upon last year's .560 OPS.
Baldoquin (hamstring) was placed on the 7-day disabled list Thursday, Alden Gonzalez of MLB.com reports. Baldoquin left Tuesday's game for High-A Inland Empire with an apparent hamstring injury, and though Gonzalez notes that the injury isn't believed to be serious, he'll land on the DL as a precaution. As a top-10 prospect in the Angels' system, it makes sense for the organization to take a cautious approach with him. He'll be eligible to come off the disabled list April 21.
Baldoquin left Tuesday's game for High-A Inland Empire with a hamstring injury, 66ers broadcaster Steve Wendt reports. He apparently aggravated the injury while running out a double in the fourth inning. Baldoquin is a top-10 prospect in the Angels system, but that says more about how bad that farm system is than it does about Baldoquin as a prospect. Consider him day-to-day.
Baldoquin was reassigned to minor league camp Thursday. The 21-year old shortstop had a solid showing with the Angels' big league camp this spring, going 3-for-8 with two doubles and four RBI over six games. He'll head down to minor league camp to get more reps and he remains a ways away from cracking the major league roster.
Baldoquin will be a non-roster invitee to major league spring training, Pedro Moura of The Los Angeles Times reports. Baldoquin, a 22-year-old Cuban middle infielder, received an $8 million signing bonus from the Angels in November of 2014. He's a big part of the team's plans for the future, but last season's .235/.266/.294 slash line at High-A Inland Empire makes it clear that his bat is nowhere close to being big-league ready. Even when accounting for his strong defensive reputation, Baldoquin is unlikely to reach the majors at any point in 2016.